Vildagliptin (LAF-237) , ≥99% , 274901-16-5
CAS NO.:274901-16-5
Empirical Formula: C17H25N3O2
Molecular Weight: 303.4
MDL number: MFCD08275142
EINECS: 630-410-0
Pack Size | Price | Stock | Quantity |
10MG | RMB39.20 | In Stock |
|
50MG | RMB55.20 | In Stock |
|
1G | RMB81.60 | In Stock |
|
5G | RMB212.00 | In Stock |
|
25G | RMB728.80 | In Stock |
|
100G | RMB2516.80 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 153-155?C |
alpha | -78.3° (c = 9.73 in methanol) |
Boiling point: | 531.3±50.0 °C(Predicted) |
Density | 1.27 |
Flash point: | 275.1℃ |
storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
solubility | Soluble in DMSO (up to 45 mg/ml), in DMF (up to 20 mg/ml), or in Ethanol (up to 20 mg/ml). |
form | solid |
pka | 15.05±0.40(Predicted) |
color | White |
Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF, or ethanol may be stored at -20°C for up to 3 months |
InChI | InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1 |
InChIKey | SYOKIDBDQMKNDQ-XWTIBIIYSA-N |
SMILES | N1(C(CNC23CC4CC(CC(O)(C4)C2)C3)=O)CCC[C@H]1C#N |
Description and Uses
Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC50=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.
The major metabolite of Vildagliptin
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H302-H315-H319-H332-H335 |
Precautionary statements | P261-P280-P305+P351+P338 |
Risk Statements | 28-38-41-48 |
Safety Statements | 24/25-26-28-36/37/39 |
RIDADR | 3077 |
HS Code | 29339900 |